WASHINGTON, D.C. (November 10, 2021) — Paula Witt has joined the Association for Accessible Medicines as Senior Manager, State Government Affairs. She will assist the state government affairs team in pursuing its advocacy goals and in representing the generics and biosimilars industry across the country.
We’re delighted to welcome Paula to the association and to complement our state advocacy efforts,
said Senior Vice President, Government Affairs, Erik Komendant. Paula brings valuable experience in tracking state legislative activity, working collaboratively to build consensus with different stakeholders and effectively communicating complex issues to a broad audience. We’re glad she’s joined the team as we prepare for the 2022 legislative sessions.
Paula comes to AAM from George Mason University Antonin Scalia Law School, where she served as Director of Judicial Education in the Law & Economics Center. She was previously Director of Legislative and Regulatory Information at StateScape and the American Council of Life Insurers.
Paula holds a BS in Chemistry from Duquesne University and a JD from George Mason School of Law.
MEDIA CONTACT:
Rachel Schwartz
202.249.7147
About AAM
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 20 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.